IL312730A - Antimicrobial peptides and methods of using same - Google Patents
Antimicrobial peptides and methods of using sameInfo
- Publication number
- IL312730A IL312730A IL312730A IL31273024A IL312730A IL 312730 A IL312730 A IL 312730A IL 312730 A IL312730 A IL 312730A IL 31273024 A IL31273024 A IL 31273024A IL 312730 A IL312730 A IL 312730A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- amino acid
- acid sequence
- position corresponding
- use according
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 title 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 claims 44
- 235000001014 amino acid Nutrition 0.000 claims 14
- 229940024606 amino acid Drugs 0.000 claims 14
- 239000004475 Arginine Substances 0.000 claims 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 10
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 5
- 239000004471 Glycine Chemical group 0.000 claims 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 208000005141 Otitis Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 208000019258 ear infection Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
- C12N15/8281—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for bacterial resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Cell Biology (AREA)
Claims (19)
1. An amino acid sequence that is 18-21 amino acids long and comprises, at its N-terminus, SEQ ID NO: 1 (KWCFRVCYRGICYRRCRD) or SEQ ID NO: (PKWCFRVCYRGICYRRCRD) or a peptide that differs from SEQ ID NO: 1 or SEQ ID NO: by one, two, three, or four amino acids, for use in a method of treating an ear infection in an animal in need thereof, wherein the amino acids differing from the amino acids of SEQ ID NO: 1 or SEQ ID NO: 29 are independently selected from the group consisting of arginine or glycine at position corresponding to position 1 of SEQ ID NO: 1; phenylalanine or arginine at position corresponding to position 2 of SEQ ID NO: 1; valine or tryptophan at position corresponding to position 4 of SEQ ID NO: 1; tyrosine at position corresponding to position 5 of SEQ ID NO: 1; arginine at position corresponding to position 8 of SEQ ID NO: 1; glycine at position corresponding to position 9 of SEQ ID NO: 1; arginine at position corresponding to position 10 of SEQ ID NO: 1; alanine, phenylalanine, or valine at position corresponding to position 11 of SEQ ID NO: 1; histidine at position corresponding to position 14 of SEQ ID NO: 1; lysine at position corresponding to position 15 of SEQ ID NO: 1; asparagine at position corresponding to position 17 of SEQ ID NO: 1, wherein said infection is a bacterial infection.
2. The amino acid sequence for use according to claim 1, wherein the amino acid sequence comprises aspartic acid at position corresponding to position 18 of SEQ ID NO: 1.
3. The amino acid sequence for use according to claim 1 or 2, wherein the amino acid sequence comprises asparagine at position corresponding to position 17 of SEQ ID NO: 1.
4. The amino acid sequence for use according to any one of claims 1 to 3, wherein the amino acid sequence comprises glycine at position corresponding to position 1 of SEQ ID NO: 1.
5. The amino acid sequence for use according to any one of claims 1 to 4, wherein the amino acid sequence comprises alanine at position corresponding to position 11 of SEQ ID NO: 1.
6. The amino acid sequence for use according to any one of claims 1 to 5, wherein, in the amino acid sequence, arginine is present at position corresponding to position 14 of SEQ ID NO: 1, at position corresponding to position 15 of SEQ ID NO: 1, or both.
7. The amino acid sequence for use according to any one of claims 1 to 6, wherein the amino acid sequence comprises arginine at position corresponding to position 14 of SEQ ID NO: 1 and position corresponding to position 15 of SEQ ID NO: 1.
8. The amino acid sequence for use according to any one of claims 1 to 7, wherein the amino acid sequence is 18 amino acids long.
9. The amino acid sequence for use according to any one of claims 1 to 8, wherein the peptide differs from SEQ ID NO: 1 by three, two, or one amino acid.
10. The amino acid sequence for use according to any one of claims 1 to 9, wherein the amino acid sequence comprises, at its N-terminus, SEQ ID NO: 1, SEQ ID NO: (RWCFRVCYRGICYRRCRD), SEQ ID NO: 3 (GWCFRVCYRGICYRRCRD), SEQ ID NO: (KFCFRVCYRGICYRRCRD); SEQ ID NO: 5 (KWCFYVCYRGICYRRCRD), SEQ ID NO: (KWCFRVCRRGICYRRCRD), SEQ ID NO: 7 (KWCFRVCYRGVCYRRCRD), SEQ ID NO: (KWCFRVCYRGACYRRCRD), SEQ ID NO: 9 (KWCFRVCYRGFCYRRCRD), SQE ID NO: (KWCFRVCYRGICYHRCRD), SEQ ID NO: 11 (KWCFRVCYRGICYRRCND).
11. The amino acid sequence for use according to claim 10 wherein the amino acid sequence comprises SEQ ID NO: 1 or SEQ ID NO: 3 or SEQ ID NO: 11.
12. The amino acid sequence for use according to claim 10 wherein the amino acid sequence comprises SEQ ID NO:4 or SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO: 8.
13. The amino acid sequence for use according to claim 1, wherein the peptide is SEQ ID NO: 1 or differs therefrom by one amino acid.
14. The amino acid sequence for use according to any one of claims 1 to 12, wherein the amino acid sequence is 19 amino acids long.
15. The amino acid sequence for use according to claim 14, wherein the peptide differs from SEQ ID NO: 29 by three, two, or one amino acid.
16. The amino acid sequence for use according to claim 15, wherein the peptide is SEQ ID NO: 29 or differs therefrom by one amino acid.
17. The amino acid sequence for use according to claim 1, wherein the sequence consists of SEQ ID NO: 1 or SEQ ID NO: 29.
18. The amino acid sequence for use according to any one of claims 1 to 17, wherein the animal is a dog.
19. A method of treating an ear infection in a non-human animal in need thereof, the method comprising administering to the animal a formulation comprising an amino acid sequence that is 18-21 amino acids long and comprises, at its N-terminus, SEQ ID NO: (KWCFRVCYRGICYRRCRD) or SEQ ID NO: 29 (PKWCFRVCYRGICYRRCRD) or a peptide that differs from SEQ ID NO: 1 or SEQ ID NO: 29 by one, two, three, or four amino acids, wherein the amino acids differing from the amino acids of SEQ ID NO: 1 or SEQ ID NO: are independently selected from the group consisting of arginine or glycine at position corresponding to position 1 of SEQ ID NO: 1; phenylalanine or arginine at position corresponding to position 2 of SEQ ID NO: 1; valine or tryptophan at position corresponding to position 4 of SEQ ID NO: 1; tyrosine at position corresponding to position 5 of SEQ ID NO: 1; arginine at position corresponding to position 8 of SEQ ID NO: 1; glycine at position corresponding to position 9 of SEQ ID NO: 1; arginine at position corresponding to position 10 of SEQ ID NO: 1; alanine, phenylalanine, or valine at position corresponding to position 11 of SEQ ID NO: 1; histidine at position corresponding to position 14 of SEQ ID NO: 1; lysine at position corresponding to position 15 of SEQ ID NO: 1; asparagine at position corresponding to position 17 of SEQ ID NO: 1, wherein said infection is a bacterial infection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595725P | 2017-12-07 | 2017-12-07 | |
| PCT/US2018/064029 WO2019113181A1 (en) | 2017-12-07 | 2018-12-05 | Antimicrobial peptides and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312730A true IL312730A (en) | 2024-07-01 |
Family
ID=65003464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL275074A IL275074B2 (en) | 2017-12-07 | 2018-12-05 | Antimicrobial peptides and methods of using same |
| IL312730A IL312730A (en) | 2017-12-07 | 2018-12-05 | Antimicrobial peptides and methods of using same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL275074A IL275074B2 (en) | 2017-12-07 | 2018-12-05 | Antimicrobial peptides and methods of using same |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11352396B2 (en) |
| EP (1) | EP3720875A1 (en) |
| JP (1) | JP7381465B2 (en) |
| KR (2) | KR102555177B1 (en) |
| CN (1) | CN111479824A (en) |
| AR (1) | AR113618A1 (en) |
| AU (3) | AU2018378035B2 (en) |
| BR (1) | BR112020009973A2 (en) |
| CA (1) | CA3082491A1 (en) |
| CL (1) | CL2020001464A1 (en) |
| CO (1) | CO2020006907A2 (en) |
| IL (2) | IL275074B2 (en) |
| MX (1) | MX2020005920A (en) |
| NZ (1) | NZ764838A (en) |
| PH (1) | PH12020550942A1 (en) |
| SG (1) | SG11202004661QA (en) |
| TW (3) | TWI786887B (en) |
| WO (1) | WO2019113181A1 (en) |
| ZA (1) | ZA202003387B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022204079A1 (en) * | 2021-03-23 | 2022-09-29 | Genvor Inc. | Antimicrobial peptides |
| CN113185576B (en) * | 2021-04-09 | 2023-05-30 | 倪京满 | Beta-hairpin type low-toxicity broad-spectrum antibacterial peptide with RRRF corner and application thereof |
| WO2023108026A2 (en) | 2021-12-08 | 2023-06-15 | Oakgrove Bio Llc | Biological production of histidine-rich peptides |
| EP4198045A1 (en) * | 2021-12-16 | 2023-06-21 | Université de Lille | Antimicrobial peptides, variants and chemical analogues thereof and their uses |
| WO2024003890A1 (en) * | 2022-06-29 | 2024-01-04 | Omnix Medical Ltd. | Novel peptide for treating an infectious disease or condition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323166C (en) * | 2003-09-18 | 2007-06-27 | 中国农业科学院饲料研究所 | Method of improving king crab element gene with higher antibacterial activity and high effect expression |
| CN101307316B (en) | 2008-07-22 | 2011-03-16 | 北京中农颖泰生物技术有限公司 | Secretion expression of antibiotic peptide CAD in bacillus subtilis and expression system of recombination bacillus subtilis |
| CN101698682B (en) | 2009-10-26 | 2012-05-23 | 陕西省微生物研究所 | Double-functional fusion protein based on antibacterial peptide, preparation method and applicaitoin thereof |
| CN101817883B (en) | 2010-03-12 | 2012-06-13 | 广东药学院 | Housefly cecropin-human lysozyme fusion protein, and preparation method and application thereof |
| CN101851620B (en) | 2010-04-21 | 2012-05-23 | 吉林农业大学 | Method for producing FGFs by utilizing edible medicinal fungus |
| WO2013006956A1 (en) | 2011-07-13 | 2013-01-17 | Phyterra Bio Inc. | Methods and uses of a modified cecropin for treating endoparasitic and bacterial infections |
| CN104177502B (en) * | 2014-08-21 | 2018-04-24 | 天津兰瑞生物技术有限公司 | A kind of histone-antibody fusion protein and preparation method |
| CN104988170B (en) * | 2015-08-01 | 2018-01-16 | 吉林农业大学 | One kind fusion antibacterial peptide and its preparation method and application |
-
2018
- 2018-11-28 TW TW110138439A patent/TWI786887B/en active
- 2018-11-28 TW TW107142356A patent/TWI746908B/en active
- 2018-11-28 TW TW109120233A patent/TW202116348A/en unknown
- 2018-12-05 MX MX2020005920A patent/MX2020005920A/en unknown
- 2018-12-05 IL IL275074A patent/IL275074B2/en unknown
- 2018-12-05 NZ NZ764838A patent/NZ764838A/en unknown
- 2018-12-05 KR KR1020207015602A patent/KR102555177B1/en active IP Right Grant
- 2018-12-05 IL IL312730A patent/IL312730A/en unknown
- 2018-12-05 CA CA3082491A patent/CA3082491A1/en active Pending
- 2018-12-05 AU AU2018378035A patent/AU2018378035B2/en active Active
- 2018-12-05 SG SG11202004661QA patent/SG11202004661QA/en unknown
- 2018-12-05 KR KR1020237023202A patent/KR102713813B1/en active IP Right Grant
- 2018-12-05 US US16/769,025 patent/US11352396B2/en active Active
- 2018-12-05 BR BR112020009973-2A patent/BR112020009973A2/en unknown
- 2018-12-05 EP EP18830562.7A patent/EP3720875A1/en active Pending
- 2018-12-05 WO PCT/US2018/064029 patent/WO2019113181A1/en unknown
- 2018-12-05 JP JP2020531448A patent/JP7381465B2/en active Active
- 2018-12-05 CN CN201880078731.4A patent/CN111479824A/en active Pending
- 2018-12-06 AR ARP180103579A patent/AR113618A1/en unknown
-
2020
- 2020-06-02 CL CL2020001464A patent/CL2020001464A1/en unknown
- 2020-06-03 PH PH12020550942A patent/PH12020550942A1/en unknown
- 2020-06-04 CO CONC2020/0006907A patent/CO2020006907A2/en unknown
- 2020-06-05 ZA ZA2020/03387A patent/ZA202003387B/en unknown
-
2022
- 2022-05-06 US US17/738,572 patent/US12054518B2/en active Active
-
2023
- 2023-09-11 AU AU2023229465A patent/AU2023229465B2/en active Active
-
2024
- 2024-09-12 AU AU2024219645A patent/AU2024219645A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL312730A (en) | Antimicrobial peptides and methods of using same | |
| IL262805B1 (en) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | |
| JP2018510622A5 (en) | ||
| FI3256579T3 (en) | Cysteine protease | |
| TR201908150T4 (en) | Peptides and their uses. | |
| áAbdel Monaim et al. | Re-evaluation of the N-terminal substitution and the D-residues of teixobactin | |
| HRP20200599T1 (en) | Antimicrobial peptide | |
| JP2014500714A5 (en) | ||
| NZ591612A (en) | Prevention, treatment and diagnosis of p.gingivalis infection with peptides | |
| NZ602522A (en) | Biosynthetic proline/alanine random coil polypeptides and their uses | |
| WO2006006195B1 (en) | Antibacterial peptides and analogues thereof | |
| CN106164087B (en) | Antimicrobial polypeptides and uses thereof | |
| Ryge et al. | New indolicidin analogues with potent antibacterial activity | |
| EP4276463A3 (en) | Peptides | |
| RU2014140231A (en) | ANTIMICROBIAL PEPTIDES | |
| RU2015146739A (en) | COMPLEXES TYPE SUGARIDE CHAIN-POLIPEPTIDE | |
| EA201990856A1 (en) | NEW ANTI-MICROBIAL AGENTS AGAINST ENTEROCOCCUS BACTERIA | |
| MX2020010071A (en) | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria. | |
| NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| RU2014101415A (en) | MODIFIED ANTIBIOTIC PEPTIDES WITH VARIOUS SYSTEM RELEASE | |
| Lignitto et al. | Preliminary investigation on the presence of peptides inhibiting the growth of Listeria innocua and Listeria monocytogenes in Asiago d’Allevo cheese | |
| TWI403330B (en) | Low hemolysis antibacterial peptide pharmaceutical compositions and use thereof | |
| JP2019523220A5 (en) | ||
| IL312731A (en) | Relaxin-2 fusion protein analogs and methods of using same | |
| TWI577697B (en) | Salt and protease-resistance of antimicrobial peptide and the manufacture thereof |